Christopher Hassan is a seasoned healthcare executive with over 25 years of experience in drug development and addiction treatment. As the founder and former CEO of Symetria Health, he pioneered innovative treatment models for opioid use disorder (OUD) and demonstrated significant cost savings for payers through national analyses of OUD patients. Previously, Chris played a key role at Reckitt Benckiser in introducing Suboxone to the U.S. market and shaping office-based treatment models for opioid dependence. He also served as CEO and President of Colonial Management Group, overseeing the largest network of methadone treatment centers in the U.S. Currently, he is focused on developing patented opioid formulations to prevent misuse and overdose. His extensive expertise and strategic vision make him a vital leader on the DemeRx Board.
Board Chairperson